ArticleScientific reports2025
Identification of dysregulated gene clusters and pathways driving ocular surface squamous neoplasia progression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular Surface Squamous Neoplasia (OSSN) represents a spectrum of ocular malignancies that threaten vision and ocular integrity. To unravel the molecular mechanisms underlying OSSN progression, we conducted RNA-sequencing on conjunctival tissues from healthy individuals and patients with OSSN. Our analysis revealed marked alterations in the expression of genes implicated in inflammation, immune dysregulation, cell cycle regulation, and cellular stress responses. Notably, genes such as TP53, CXCL9, CXCL11, IL6, TNFα, MMP7, MMP9, GSTM1, IFNα, and IL1β showed significant dysregulation in OSSN samples compared to controls. Pathway enrichment analysis highlighted the activation of Interferon-α, Interferon-γ, and IL6/JAK-STAT3 signaling, alongside pathways regulating inflammatory response, p53 signaling, G2M checkpoint, and apical surface integrity. Together, these findings indicate that OSSN is characterized by a pro-inflammatory and proliferative transcriptomic profile driven by chronic immune signaling and disrupted cell cycle control. These findings provide novel insights into the transcriptional landscape of OSSN and identify key pathways that may be targeted for improved diagnosis and therapy. The molecular insights provided by this study can potentially inform stratified management approaches and aid in the development of novel treatments for this challenging ocular surface malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.